Amendment to exclusive patent, know-how and technology license to make, have made, develop, research, improve, use, process, offer, import, sell and distribute therapeutic and prophylactic products related to LHRH antagonist compounds, for uses in the biomedical field, including oncology and reproductive endocrinology treatments, including breast and prostate cancer, endometriosis, uterine fibroid, fertility, polycystic ovarian disease and precocious puberty.